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Abstract
Background: With the globalization of clinical trials, large developing nations have substantially increased their
participation in multi-site studies. This participation has raised ethical concerns, among them the fear that local customs,
habits and culture are not respected while asking potential participants to take part in study. This knowledge gap is
particularly noticeable among Indian subjects, since despite the large number of participants, little is known regarding what
factors affect their willingness to participate in clinical trials.
Methods: We conducted a meta-analysis of all studies evaluating the factors and barriers, from the perspective of potential
Indian participants, contributing to their participation in clinical trials. We searched both international as well as Indian-
specific bibliographic databases, including Pubmed, Cochrane, Openjgate, MedInd, Scirus and Medknow, also performing
hand searches and communicating with authors to obtain additional references. We enrolled studies dealing exclusively
with the participation of Indians in clinical trials. Data extraction was conducted by three researchers, with disagreement
being resolved by consensus.
Results: Six qualitative studies and one survey were found evaluating the main themes affecting the participation of Indian
subjects. Themes included Personal health benefits, Altruism, Trust in physicians, Source of extra income, Detailed
knowledge, Methods for motivating participants as factors favoring, while Mistrust on trial organizations, Concerns about
efficacy and safety of trials, Psychological reasons, Trial burden, Loss of confidentiality, Dependency issues, Language as the
barriers.
Conclusion: We identified factors that facilitated and barriers that have negative implications on trial participation decisions
in Indian subjects. Due consideration and weightage should be assigned to these factors while planning future trials in
India.
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Introduction
Enrollment and individual subject completion rates are
arguably the most demanding [1] phases of a clinical trial. One
of the most important factors in a trial’s success is potential
participants’ willingness to enroll. Past studies have identified a
wide variety of determinants of this factor including, education
[2,3], age [4], means of communication [5], race [6–9], language
[10], patient preference for a certain treatment [11], and a
multitude of other personal reasons [12]. Although this list might
seem comprehensive, these factors cannot be generalized to
individuals from different cultures with divergent lifestyles, social
environments, religious beliefs, and economic conditions. This is
especially problematic because large culturally diverse countries
such as India are playing a more significant role in global trials.
India is increasingly recognized as a site for health research in part
because of it’s large population and growing research capabilities
[13]. However, to our knowledge no previous studies have
consistently addressed the main factors affecting willingness to
enroll in clinical trials among Indians, a key determinant in a trial’s
success.
India’s prominence as a suitable location for health research has
emerged partly because of its potential for enrolling patients in
clinical trials [14,15]. India has one of the largest enrollment rates
in the world, with rates as high as ten times greater than the ones
in the United States for selected trials [16,17]. With a large and
heterogenous population, an additional advantage in India is that
several diseases have incidence rates similar to other developing
and developed countries [18]. However, critics have expressed
concerns over the ethical nature of these enrollment rates citing
widespread poverty, illiteracy, and lack of understanding regarding
their local culture and customs. [19].
Although there is an extensive literature [20–22] evaluating the
factors promoting and precluding participation in clinical trials
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that focus on understanding the specific attitudes and willingness
to participate within the Indian population. Extrapolation of
conclusions drawn from other populations to Indian subjects is
unreliable, since previous studies have consistently demonstrated
important differences across different cultural groups [23].
Examples include cultural differences in trial conditions [24] and
financial and social support [25–27].
Given the significance of specific cultural factors affecting
enrollment and the central role of India in global trials, the
objective of our study is to conduct a meta synthesis of qualitative
studies that evaluated factors contributing to participation of
Indians in clinical trials.
Methods
Research question
Our study addressed an important research question as what
are the factors, from the perspective of potential Indian
participants, that contribute to their participation in clinical trials.
To determine factors and barriers contributing to participation in
clinical trials, we evaluated qualitative studies and surveys
available from the existing literature.
Ethics
We did not apply for IRB approval as we conducted a
qualitative metanalysis based on published literature.
Search Strategy
Two reviewers (MV, AP) independently performed a systematic
search of the following online databases: Pubmed (1985 to 2007),
Cochrane (1983 to 2007), Medind (April 1985 to 2007), Scirus
(1980 to 2007), Medknow (1986 to 2007), and Openjgate (2000 to
2007). Of these databases, Medind, Medknow, Openjgate are
Indian databases.
We initiated our search strategy by using a set of keywords
[Appendix S1] relevant to our research question. We used these
keywords individually and in different combinations to ensure
identification of the relevant literature. Based on the articles found
through this initial search we then created a list of related Medical
Subject Headings (MeSH) Terms. [Appendix S2] Next we used
these MESH terms individually and in various combinations
[Appendix S3] using Boolean operators to conduct a detailed
search.
To make our search more comprehensive, we also retrieved and
reviewed the bibliographic references of all the full texts which
were read thoroughly to retrieve the relevant articles. Through this
method we identified study titles or abstracts that were related to
our topic. We also reviewed articles listed under the ‘‘Related
articles’’ link in PubMed. [28]. Finally, we subscribed to RSS (real
simple syndication) feeds for the search strategies that we had
devised & implemented in online databases, to track new studies
(matching our requirements) that might be published after we
completed the literature review. Since two reviewers in our team
(MV and AP) were fluent in local Indian languages (Hindi and
Marathi), we tried to extend the search to databases in these
languages. This step was limited by the lack of online publication
databases in Hindi and Marathi.
Selection
We defined selection criteria to filter study articles and shortlist
articles that would qualify for the meta synthesis and help us
answer our research question. Both reviewers (AP and MV)
independently evaluated the study articles that were identified
based on our search strategy.
Inclusion Criteria. We included studies with the following
characteristics: prospective studies; confined to Indians (Indian
resident or of Indian origin); using experimental (trials) or
qualitative methods (interviews, focus groups, ethnographic, or
survey) to collect data; studies whose outcome measures included
factors affecting participation of Indians in clinical trials, and full
text articles.
Exclusion Criteria. We excluded studies with the following
criteria: Studies that did not directly evaluate potential participants
but rather, evaluated factors influencing participation by analyzing
retrospective clinical trial data, studies that evaluated other Asian
populations or American Native Indians, unpublished articles,
dissertations and abstracts without full text. Our goal was to
evaluate the reasons for participation in clinical trials of potential
subjects. Since subjects who had already agreed to participate in a
trial would have a significant degree of confirmation bias [29,30],
we decided to exclude them from our sample. Articles in languages
other than English, Marathi and Hindi were also excluded since
the study team was not conversant with other languages.
After the finalization of inclusion and exclusion criteria, one of
us (SP) used these criteria to perform an independent search. This
reviewer was unaware of the aim of our study and was only given
the inclusion and exclusion criteria and was asked to retrieve the
related articles. This was an attempt to confirm and cross check
the findings of other 2 reviewers (AP and MV) as well as avoid
missing any relevant articles.
Finally, we screened the retrieved studies by reviewing them first
by title, then by abstract and last by full text, and at each step,
excluded those which did not satisfy the selection criteria.
Hand search
We classified the initial list of articles according to the journal in
which they were published, so that we could then identify journals
that had published most of the articles in our list. Since the focus of
our research question was on Indian potential participants in
clinical trials, we decided to concentrate only on Indian journals as
we believed that they had a higher chance of publishing articles
that matched our requirements. We manually searched through
each issue of the following online journals: The Indian journal of
medical research (Full text archive, Jan 2003 to Jan 2008) and
Indian Journal of medical sciences (Jan 1990 to Jan 2008).
Communication with authors
In order to confirm that we had identified and retrieved all
relevant study articles, we communicated via email with the
authors of these study articles to inquire about the existence of any
other published studies related to our research question.
Validity assessment
To assure that all the relevant data were retrieved, we asked a
third researcher (SP) to repeat the literature search using our
inclusion and exclusion criteria. We neither informed this
researcher about the aim of the metaanalysis nor shared the list
of studies retrieved by us earlier. Discrepancies were resolved by
consensus.
Data abstraction
Each researcher (MV,AP,SP) independently extracted qualita-
tive data from the included studies into a spreadsheet. All data was
segregated under specific headings including: aim, study design,
study period, eligibility criteria, geographic location, population
Indians Trial Participation
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number of drop outs, data analysis, outcome measures and
qualitative quotes.
Study characteristics
We collected descriptive data for each study included in our
meta synthesis. It included demographic details of participants like
age and ethnicity, country where the clinical trial was conducted,
intervention details (including study questionnaire) and outcome
definitions.
Qualitative data synthesis
Articles included in our study either reported quotes from their
interviews or reported percent of study population that provided a
specific response to each survey question. In order to ensure data
integrity, we populated the data abstraction sheet with these
quotes and percent responses for each question. Each quote and
response was then reviewed by three researchers (AP, MV & SP) to
generate emerging themes. Disagreement during this process was
resolved by consensus. The final abstracted spreadsheet was
reviewed by 4th reviewer (RP) to resolve any discrepancies. Next
we categorized the themes into 2 groups: Factors favoring
participation in clinical trials and factors serving as barriers to
participation in clinical trials. We also listed quotes from each
study that justified the final themes.
Percentage retrieval for each of the themes
Although the primary goal of our study was to carry out
qualitative data synthesis, we thought it would be equally
important and interesting to provide the percentage of participants
contributing to each of the theme. We determined the average for
similar responses in each study. Next, we calculated the total of
similar responses from all studies and reported it as a percentage.
This method allowed us to report both quotes from interviews and
responses to survey questionnaire, thus minimizing data loss.
Results
Search Strategy Results
The initial review of the literature yielded 327 study articles.
After reading the abstracts of these articles, we excluded 147 of
them because of the following reasons: 1. They were not clinical
trials, 2. They had no Indian population, 3. As the studies did not
have desired outcomes, 4. Other study articles were removed
because they dealt mainly with educational/prevention programs,
screening programs, or medical service camps. We then retrieved
and evaluated the full text for the remaining 180 articles, leading
to the further exclusion of 171 articles because 1. There full texts
were not available, 2. They had no Indian population, 3. As the
studies did not have desired outcomes, 4. Other study articles were
removed because they dealt mainly with educational/prevention
programs, screening programs, or medical service camps. The
final list comprised seven studies matching our inclusion and
exclusion criteria. This flow chart is summarized in Figure 1.
We retrieved three studies by the same author (Hussain
Gambles), two of which were published in year 2004, and the
third was published in 2006. Since one of these three studies was
a combination of two studies [31], we considered combined study
for inclusion in the current meta synthesis and excluded the other
two individual studies [32,33]. Hand search did not yield any
studies matching our selection criteria. The final list of seven
articles, all using a qualitative research design, is listed under
Table S1.
Study characteristics
Out of the seven studies included in our meta synthesis, four
studies were conducted in India and exclusively reported data on
Indian population. The remaining three studies were conducted in
multiple locations like Singapore, United states (US), United
kingdom (UK), France, Poland, Italy, Spain and others. They had
a mixed ethnic population. Of the seven studies, three primarily
focused on studying subject participation in general while other
three focused on HIV vaccine trial participation and one study
focused on subject participation in genetic research. The number
of Indians enrolled in all the studies is reported in Table S1. The
minimum age of participants enrolled in the seven studies was
above 15 years except for two studies that did not report this
information [24,34]. We present results derived from the seven
studies based on the methods used in each study; namely focus
group discussions, semi structured questionnaires and interviews.
For example, quotes from focus group discussions and interviews
contributed to emerging themes which are presented in table S2
and S3, while data from the studies that used semi structured
questionnaire are presented in the form of percentages in the same
tables.
Validity assessment
The list of study articles retrieved independently by the third
reviewer matched the ones that the other two reviewers (AP and
MV) had retrieved.
Emerging themes
Thirteen themes were generated after thoroughly reveiwing and
analyzing all the seven shortlisted study articles dealing in
willingness of Indian subjects to participate in clinical trials. The
themes were subdivided into two groups based on factors that
facilitated or served as barriers to participation in clinical trials.
Factors favoring participation (Table S2)
Personal Health Benefits 48%. All seven studies
contributed to this theme. Potential participants are more likely
to participate if they are convinced that the clinical trial output will
benefit them in terms of good health, protection from or
prevention of some disease. [35] ‘‘… I think a lot of people probably
you, would find ‘what’s in it for me’. I’m just thinking if my mum and dad
were approached, I don’t think they would get involved.’’ (LI5F3)" [31]. The
same is true for relatives who influence decisions on participation.
If they are convinced that the participant will personally benefit,
they frequently encourage participation. ‘‘… if it makes their wife
better and she’s going to make the chapattis again, then yes they’ll sign it
[consent forms] … and again that’s from education and that’s from their
family background, and also what sort of job they do in this country.’’ [31].
Free treatment to self or kin, pain relief for self are some other
examples that were also valued. Patients with incurable diseases or
at the terminal stage of life, choose to participate with the hope
that the trials may improve their condition or cure them. [36]. In
case of potential participants of a HIV vaccine trial, personal
protection from possible HIV infection during and after the trial
significantly influenced their decisions. ‘‘Initially it (the HIV vaccine)
will give 75% protection. At the end of the research, it will be 100%, hence
there is no harm.’’ [37]. Notably, married women from the same
study cited personal safety from HIV infection as a motivator to
participate in trials. ‘‘We may be unaware of the behavior of the men folk.
If they had gone astray, there are chances of us also to get infected. By taking the
vaccine, this can be prevented’’ [37].
Altruism 43%. Altruism was present as an emerging theme
in all seven studies. Contribution to collective good as well as to
Indians Trial Participation
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decisions on participation in clinical trials: ‘‘I feel glad to take social
risk’’; ‘‘Do something that is good for the world’’ [34]. The sense of
goodwill by helping in the development of a potential cure or
vaccine and thus avert an epidemic was also notable. ‘‘helping to find
a vaccine that works’’, ‘‘helping to stop the epidemic.’’ [35]. Finally, helping
to prevent a killer disease like HIV and making it preventable were
other responses corroborating this theme. ‘‘HIV will become
preventable like polio’’ [35]. ‘‘HIV/AIDS is a killer disease. It would be
wonderful if there is going to be a vaccine for it. We are confident that it would
come.’’ [37].
Methods for motivating participants 34%. This theme,
which describes methods to motivate participation in clinical trials,
emerged from three out of seven studies. Respondents
communicated their preference for trials initiated by research
institutes or government agencies. They were more inclined to
participate, if information on clinical trials was provided through
government owned television channels. The same was true in case
of HIV vaccine trials where it was apparent that potential
participants placed a lot of faith in government endorsement and
were more likely to believe that it was safe to participate. ‘‘If it is
done through the government, many people would come forward to take it’’.
Figure 1. Flowchart with inclusion and exclusion of articles.
doi:10.1371/journal.pone.0010730.g001
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vaccine, it will surely be safe. So we can take the vaccine without fear.’’ [37].
Dissemination of clinical trial-related information during
healthcare camps could also influence potential participants:
‘‘Sometimes they organize specialists to come in so we can talk about our
health problems. If they talked about clinical trials and medical research I think
many people would take an interest and be willing to participate.’’ (LI20M3)"
[translated from Gujarati] [31]. Other motivating factors ranged
from advice by regular/usual physician (51/128, e-mail notifica-
tions =(47/128, traditional media (eg. Newspapers, magazines,
TV, radio) (42/128), a relevant advocacy organization/patient
support group (26/128, internet websites (53/128, Harris
interactive [38] (60/128) and family/friends (28/128). Widespread
and educative advertisements especially in places of high public
thoroughfare were also recommended by potential participants of
a HIV vaccine trial. ‘‘The advertisement for the polio vaccination is
widespread and educative. HIV vaccination may be done on similar lines. It
would be beneficial if HIV vaccine is also given in railway stations and bus
stops.’’ [37].
Source of extra Income, 31%. Responses that pointed
toward this theme were noted in four of seven studies. Willingness
to participate was more pronounced if monetary remuneration
was involved. Respondents expected an incentive for clinical trial
participation in terms of monetary gains or incentives such as gifts
and insurance coverage. Additionally potential participants in
HIV vaccine trials demanded that the monetary/insurance benefit
be guaranteed to them or next of kin in case of death. ‘‘We want a
written guarantee plus insurance policy. The document should specify that, in
the event of death (of the person after taking the vaccine), his family would be
given full support.’’ "Security assurance that in the case of amiss, families
would be taken care of.’’ [37].
Detailed knowledge 21%. The need to keep participants
informed about the potential risks involved in clinical trial
participation was reinforced in multiple studies. Respondents
indicated that knowledge about the involvement/non involvement
of risk and information on current medication tended to influence
their decisions. This was apparent when participants asked for
more information before they agreed to, for example, donate
blood specimens. In case of HIV vaccine trials, participants
stressed on the need of education, information and clarification
about the nature and characteristics of HIV vaccine. ‘‘The ELIZA
test will be positive due to vaccination. We should tell those persons who had
taken the vaccines that the positivity would disappear after some time’’. [37].
Specifically they wanted answers to questions like the frequency,
site of administration, period of protection and effectiveness of
HIV vaccines. ‘‘Community members would want to know about the
frequency of the vaccines and the site administered, how it might impact
marriage, how long the HIV positive result will last, how long will the vaccine
protect for, and will the vaccine be effective.’’ [37]. Finally, terminology,
language and style played an important role in communicating
study-related information to the potential clinical trial participants:
‘‘I understood bits of it, some things I didn’t understand. The second time I
went I took my daughter with me. She explained what he said and that they
will offer to get somebody to translate for me. When I visit the doctor I
occasionally take my daughter because of the terminology used.’’ [31].
Trust in Physicians 8%. This theme was present in five out
of seven studies. Respondents in the qualitative studies expressed
the important role of family physicians/general practitioners (GP)
in the clinical trial participation - decision-making process. In
comparison to the educated, the uneducated are more inclined to
follow their GP’s advice in relation to clinical trial participation.
This can be seen from the quote ‘‘… well I think especially the ones that
are uneducated, they’re easily persuaded, easily persuaded because I mean, okay,
I regard my GP pretty highly, okay, but I also realise that GP just offer an
opinion. Whereas if I was uneducated, GP’s God … the Asian community
always looks at, well doctors being the top profession, the top everything.
Whatever they said they will believe they will do it, you know. I mean I would
possibly be inclined, but they would definitely do it, I reckon.’’ [31].
Factors serving as barriers to clinical trial participation
(Table S3)
Mistrust of trial organizations, 26%. This theme emerged
from responses observed in four out of seven studies. Respondents
made personal inferences about the main aim of some trials and
felt they were ‘‘treated as guinea pigs.’’ Also, they felt there was
always a possibility of placebo administration that would not
benefit them in any way, indicating that mistrust was a main factor
influencing their refusal to participate. On the other hand, it was
observed that family doctors enjoyed their patients’ trust. This was
evident from the potential participants’ desire to consult their
family doctors to advise them on safety in relation to participation
in trials.
Concerns about efficacy and safety of trials, 21%. This
theme was present in three out of the seven studies. Potential
participants voiced their concerns about safety procedures as well
as possible side effects and health risks that might be associated
with clinical trials. They were also concerned about the unproven
nature of the therapy that they would be subjected to. Specifically
in relation to vaccine trials, patients reported concerns related to
unknown efficacy and long-term adverse effects.
Dependency Issues, 19%. Responses from two out of seven
studies gave rise to this theme. Respondents frequently depended
on family, friends or society in general to guide their decision to
participate in clinical trials. Participation of a friend served as an
example and encouraged participation because it made them feel
more comfortable and as if they were not alone in their decision:
‘Can come if a friend comes’ and ‘Cannot come alone.’ Finally, the need to
consult children, spouse or other family members was strongly felt
before arriving at a decision. ‘Have children at home…’; ‘Do not have
knowledge, will ask husband.…’; ‘Has to see what husband says…’;
‘Husband does not allow, then I will not come…’ [34]
Loss of Confidentiality, 17%. This theme emerged from
responses noted in four out of seven studies. Respondents were
concerned about privacy safeguards and cited the potential
negative impact of loss of confidentiality on personal life,
marriage, insurance and employment when describing reasons
for not participating in clinical trials. Respondents also feared that
personal health matters would be disclosed in a clinical trial which
may end up causing personal harm to them. Accordingly they
placed a lot of importance on keeping their personal information
confidential. ‘‘If you are checking whether I have the gene for cancer or heart
diseases, it is ok. However, my privacy is very important especially if you are
checking for a gene for a personality disorder. I dont want people poking their
noses into my family‘‘ - Indian female manager.’’ [39].’’
The same concern was echoed by potential participants of HIV
vaccine trials. Notably the social stigma attached to HIV/AIDS made them
highly concerned about the confidentiality of their personal information.
‘‘Friends will suspect us if we undergo HIV testing,’’ and ‘‘People do not
consider HIV/AIDS as an ordinary/another disease. The stigma attached to
the disease is persisting still. Other people may get to know about the result
when the trials are being conducted. No one will come forward to take part in
the vaccine trial if there are going to be chances that others/outsiders may know
the result. Why? Even I shall not come. Men having sex with men are not
given/accorded status in society. We agree that you are working for a worthy
cause. But if everyone (public/outsiders) is going to know about their HIV
status, none of the men having sex with men will agree for the trial. It would be
better if the stigma attached to HIV/AIDS were removed from the minds of the
public before the vaccine is introduced.’’ [37].
Indians Trial Participation
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this theme, which primarily related to the challenges and
difficulties involved in clinical trial participation that ultimately
burden the subject. These include trial procedures and protocol
that have the potential to disrupt routine life and cause
inconvenience to a subject. For example, respondents cite time
constraints, travel, intake of additional and unnecessary drugs in
four studies. On the other hand, trials that were deemed to be
more convenient and less disruptive of routine life enhanced
participation [36]. While commenting on retention in HIV
vaccine trials, potential participants showed a preference for
additional facilities that would reduce the impact of trial
participation on their daily lives. Examples such as a paid leave
from office, location of trial venue near the house and short
duration of trials were noted. [37]. Finally, frequent blood
specimen collection was perceived to be inconvenient and in
conflict with busy schedules: ‘How often will blood specimens be taken? If
you come very often, it will cause us a lot of inconvenience. We are all very
busy.’ (Indian Female factory worker) [39].
Psychological reasons, 6%. Numerous sub themes dealing
with psychological factors influencing subject decisions to
participate in clinical trials contributed to the formation of this
theme. These factors ranged from plain fear to fear of injection/
stigma/blood tests as well as disinterest in participation: ‘‘Well I
mean it’s just, you know, sort of fright, that’s all I can think of really, fright.
Fright and the dangers I can associate with it, that’s all. I mean, okay, it’s
selfish in a way because other people try it, trial themselves for me.’’ [31].
Some participants were anxious about the possibility of detection
of something new and unpleasant that might result in an incurable
disease while others were plainly not interested.
Language 1%. This theme was found in only one out of
seven studies. Respondents preferred the communication of
clinical trial information in a simple and lucid manner.
Additionally, language barriers frequently caused respondents to
have difficulty understanding the procedures, safety, and benefits
of the ongoing clinical trials, which subsequently resulted in
neglect and non-participation in clinical trials: ‘‘… it’s hard to
understand the language because it’s complicated in the words that they
[doctors] use. And we don’t know any different or how to go about arguing with
him.’’ [31] and ‘‘did not understand’’ [9].
Discussion
Our meta analysis retrieved, selected and reviewed qualitative
studies that evaluated the factors influencing participation of
Indian subjects in clinical trials. The meta synthesis of factors cited
by Indian subjects provides a better picture of their mindset by
revealing what favors or hampers their decision to participate in
clinical trials. The emerging themes from our study broadly fall
under two categories: Factors favoring participation and factors
restricting participation. The former includes the themes: personal
health benefits, altruism, trust of physicians, source of extra
income, detailed knowledge about trials and methods for
motivating participants. On the other hand the latter category
includes: mistrust on trial organizations, concerns about efficacy
and safety of trials, psychological reasons, trial burden, loss of
confidentiality, dependency issues and language. Our study also
tried to derive the quantitative data in terms of percentage of
population for each of the themes. Though these figures may not
be precise and accurate they do represent the broad percentages
and would certainly needs attention as to which of the theme
might need more focus in terms of any rectification that might
have to be implemented either to eliminate barriers or to
encourage participation.
Our study focused specifically on Indian population for the
following reasons: 1. India as a part of the BRIC nations is the
current hotspot for the conduct of clinical trials. 2. Its huge and
diverse (racially and ethnically) population is considered favorable
for clinical trial implementation because it ensures rapid
enrollment and enhances the generalizability of results. Addition-
ally racial and ethnic groups have their own unique ways of
looking at, interpreting and deciding on clinical trial participation
on account of numerous factors such as their beliefs, religion,
knowledge about experimental studies [40]. Therefore, it is
essential to understand and evaluate factors that influence their
decisions to participate in clinical trials.
Indians were highly willing (prevalence=47%) to participate in
clinical trials when they were convinced that there were personal
healthcare advantages. The influence of personal benefit on
important decisions like participation in a clinical trial is a natural
human tendency and has been confirmed in all major ethnic
groups [40]. It can take a variety of forms such as access to free
medicines and latest treatments [41–44], possible chance of cure
by the trial intervention [20], possible relief by trial intervention
[45] and possible protective benefit through vaccine trials are some
of the most common forms. On the other hand, personal benefit
does not always spur participation in trials as apparent from
factors like ’non availability of alternative treatments’ cited in
previous studies [25,31]. It is important to note that although
personal health benefit is often thought of as an individual driver
of participation, it may often be affected by cultural, socio-
economic and healthcare conditions prevailing in a country. For
example, populace hailing from low socio economic background
and with little access to quality healthcare are attracted by the free
treatment and financial incentives provided in clinical trials. In
contrast to the factor ’personal health benefit,’ 43.36% subjects
also believed in altruism which is a selfless wish to benefit peers,
society and science. For example, a patient may participate not
only because they hope to be cured but also because they want
others to be cured. Previous studies have also simultaneously
encountered these contrasting factors. [41,42]. Altruistic motiva-
tions for participating in trials are evident when healthy volunteers
participate in clinical trials with the aim of benefiting ailing
patients around the world. This inclination has been noted in a
number of ethnic groups [31,41,44,46–48] and among HIV
patients who are usually influenced by safety and personal benefit
concerns [42,49–51]. Apart from these two factors, the theme –
‘trust in physician’ (7.9%) reflects the fact that patients frequently
rely on their doctors advice while deciding to participate in clinical
trials. Patients consider their physicians as their health guide and
frequently trust them blindly either out of respect, feeling of
indebtedness or based on the belief that their physician would
never misguide them. As a result, when physicians ask their
patients to participate in a clinical study, they are unlikely to
refuse. Along similar lines, previous studies mention the role of 1.
physician recommendation, communication and encouragement
and 2. sharing trial information with family physicians
[20,25,48,52–55]. Previous studies also confirm that a converse
relationship (mistrust on physician) has a significant impact on trial
participation [20,56].
Though personal health benefits and altruism were the major
influencing factors, monetary gain also emerged as a significant
theme in our study. It has also been documented in other similar
studies [57]. In a developing country like India where poverty is
rampant, participating in trials that offer monetary incentives is an
extra source of income. Even when the trial does not offer any
monetary compensation, the free care and treatment serves as a
strong attraction for patients who otherwise can not afford the cost
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distort potential participants’ judgment towards trial participation
is significant [58]. As per the metasynthesis, ‘‘detailed knowledge’’
about the objectives and procedures in the clinical trial enhances
trial participation. This is empirically achieved through an
informed consent sheet and a verbal explanation to rule out
possible misconceptions about the trial. Lack of detailed
information can raise concerns [20], and lead to non participation,
while hiding any information or furnishing incomplete information
would amount to violation of the ethical conduct of the trial.
Motivational methods like newspaper, tv ads [43], newsletters,
mail shots [1] and audio visual media can further enhance
recruitment by increasing awareness, clarifying misconceptions if
any as well as educating participants about clinical trials. Although
it was predominant across all studies, one study made a contrasting
observation: complete or partial disclosure of the consent process
(where patients are provided detailed trial information) did not
alter the number of subjects consenting to participate [24]. Rather
subjects relied on the explanation and answers furnished by the
researchers. Factors like treating physician, poverty and illiteracy
might have led to this observation. Summing up, factors like
personal health benefit, altruism and monetary gains being
subjective lie in the personal decision making domain. On the
contrary themes like trust in physicians and detailed knowledge
suggest that physicians play an important role in recruitment and
they should be well trained and knowledgeable about the trial.
While trust in physician favored trial participation for 7.9% of
the subjects, mistrust on physicians and researchers was also
expressed as a barrier by 26.27% of the subjects. Other factors like
lack of faith and fear towards the healthcare system [23,59,60], the
notion of ’guinea pig treatment’ [40] and mistrust in clinical
research [23,48,60–63] have been shown to negatively influence
subject participation in clinical trials. It is important to note there
can be a different effect on trial participation depending on
whether the treating physician, trial recruiters or researchers were
involved in recruitment. While trial recruiters may not be trusted
as much as physicians, they often have more training and time for
recruiting potential trial participants. Differences in the percep-
tions about trust or mistrust on trial organization, researchers or
pharmaceutical industries can be due to multiple ethnic variations,
previous experience in trial participation, language and literacy
[64–65]. Promoting trust and identifying other sources of mistrust
in the trial organization are possible solutions that can enhance
subject trust [66,67]. A lack of detailed knowledge, motivation
methods and proper communication methods can significantly
enhance the mistrust of subjects in trials. It can also contribute to
the theme – ‘concerns about safety and efficacy of trials’ where
unproven efficacy, side effects and health risks of experimental
treatment may deter subjects from participating in clinical trials.
Similar findings have been documented in the Chinese population
[25], in cancer trials [52] and placebo controlled trials [44]. The
metasynthesis also identified ’psychological reasons’ that deter
subjects from trial participation. Some examples were 1.
preconceived notions about various aspects of clinical trial
participation such as pain and number of tests that they (subjects)
would have to undergo and 2. the social stigma involved. This is
more pronounced in the case of HIV vaccine trial participation
where participants may 1. fear serious adverse health consequenc-
es, 2. fear the possibility of getting infected due to vaccination and
3. fear on being denied health insurance coverage [68]. Apart
from the misconceptions and preconceived notions, some subjects
also found trial participation to be a burden as it requires extra
time and effort. Participation often meant that subjects would be
required to make additional visits to the doctor, spend more time
traveling and consume additional drugs. When this burden is
decreased, Indian subjects are more likely to participate in clinical
trials. Other studies have noted that living at a distance from the
trial site and having to participate in a trial with multiple follow up
visits tend to be burdensome for the subject and acts as a barrier to
clinical trial participation. [21].
In addition to the factors listed above, 17.08% of Indian subjects
expressed ’privacy and the negative impact of loss of confidenti-
ality’ as an important concern. Maintainence of confidentiality in
order to ensure integrity and privacy of participant information
has been emphasized and acknowledged in previous studies [69].
Additionally, confidentiality issues and breach of confidentiality
have been a concern in genetic association studies [26] as well as in
cancer clinical trials [21]. On one hand when subjects were
concerned about the maintenance of privacy and confidentiality, a
sizable number (18.65%) seeked advice and were dependant on
relatives, peers and friends while making their decision. In India
and other parts of Asia, patients frequently discuss health issues
with family and friends which contradicts the American culture,
where doctors typically do not even discuss or disclose a patient’s
health information to their family members [25]. The involvement
of family members in decisions about healthcare is a cultural factor
that has also been identified in studies of Chinese subjects [25]. In
contrast, studies of African Americans have shown that healthcare
decisions are highly individualized and autonomous and the
involvement of family members can actually inhibit, rather than
promote participation in clinical trials [8,70–72]. Conveying the
right information in a simple and clear manner as well as in a
language that they understand is important for ensuring optimal
delivery of clinical trial information to subjects. Indian subjects in
our meta synthesis confirmed this fact when they expressed
language and miscommunication as potential barriers to trial
participation. Language has also been identified as a barrier by
Chinese subjects [25], older south asian population in UK [31] as
well by other populations [73,74]. In fact, it has been argued that
language barrier can lead to mistrust which can negatively
influence trial participation. In order to avoid language barriers,
several methods have been introduced such as: translation into the
local language and the use of translators to converse with potential
participants in their local languages. For example, since the
primary language of the consent form is usually English, several
translations of the consent form are made as per the local
requirements. This does facilitate understanding of the study by
literate people, although it remains unclear how much they
actually understand. It has also been emphasized that consent
forms should be written for lay man and avoid highly technical
language. However, in practice this is not always possible and the
use of specialized terminologies in the consent form may cause
confusion for the subjects.
Because results from qualitative studies are conducted with an
aim to reach depth rather than external validity, the combination
of results needs to be subsequently verified through studies
evaluating external validity such as population-based surveys.
Also, since India is a very diverse country with a variety of
ethnicities, religious beliefs, and cultural heritages, these results
might vary across different groups, more granular investigations
being required once more studies are made available. One other
limitation of our study is non availability of full texts of twenty two
articles which we had to omit without any option with us.
Our meta analysis identified factors facilitating trial participa-
tion specifically for Indian subjects. In order to maintain its status
as a hub for clinical trials, India needs to take steps to ensure
adequate trial participation. Insights into the mindsets of Indian
subjects in relation to trial participation can guide investigators
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consideration of these factors during the planning stage may lead
to delays in the trial enrolment and subsequent implications on
trial completion and costs. There are several other reasons and
factors associated with the decision to participate in a trial that
have been expressed by other subjects belonging to different ethnic
groups from various parts of the world. However, they remain
specific to the region, ethnicity, the disease under study like HIV,
cancer, type of intervention-invasive/non invasive, type of study
design-use of placebo or any other.
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